Francois Brisebois
Stock Analyst at Oppenheimer
(1.96)
# 3,151
Out of 4,996 analysts
88
Total ratings
37.5%
Success rate
-7.1%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $5.99 | +33.56% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $3.52 | +70.45% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $8.80 | +809.09% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.44 | +194.12% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.73 | +131.21% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $56.29 | +27.91% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $27.51 | +121.74% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $10.67 | +87.44% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $5.80 | +382.76% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $15.34 | +95.57% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $163 | $52.02 | +213.34% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $13.15 | +318.25% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $19.05 | -21.26% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $6.94 | -13.54% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.01 | +265.45% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $23.26 | -39.81% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.51 | +454.32% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $14.89 | +336.53% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.07 | +97.24% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $5.86 | +2,493.86% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $17.89 | +101.23% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.21 | +28,069.01% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.66 | +325,201.20% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.09 | +255.99% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $4.63 | +288.77% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $5.80 | +762.07% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.40 | +231,328.57% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.99
Upside: +33.56%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $3.52
Upside: +70.45%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $8.80
Upside: +809.09%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.44
Upside: +194.12%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.73
Upside: +131.21%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $56.29
Upside: +27.91%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $27.51
Upside: +121.74%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $10.67
Upside: +87.44%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $5.80
Upside: +382.76%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $15.34
Upside: +95.57%
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $52.02
Upside: +213.34%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $13.15
Upside: +318.25%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $19.05
Upside: -21.26%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $6.94
Upside: -13.54%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.01
Upside: +265.45%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $23.26
Upside: -39.81%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $4.51
Upside: +454.32%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $14.89
Upside: +336.53%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.07
Upside: +97.24%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $5.86
Upside: +2,493.86%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $17.89
Upside: +101.23%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.21
Upside: +28,069.01%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.66
Upside: +325,201.20%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.09
Upside: +255.99%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $4.63
Upside: +288.77%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $5.80
Upside: +762.07%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.40
Upside: +231,328.57%